Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Marco Dolci intends to retire as President of the Cardiopulmonary (CP) Business Unit (BU) by December 31, 2023. Dolci will continue in his role and support the transition of responsibilities through the end of the year. Franco Poletti will serve as Interim General Manager of CP to support the transition efforts, in addition to his current role as Vice President of CP for Europe, effective immediately. LivaNova will retain a leading international executive search firm to assist with the search for a permanent successor for the President of CP.

“On behalf of the Board, the executive leadership team and the employees at LivaNova, I would like to thank Marco for his leadership over the last 6.5 years, especially during the development and launch of the Essenz™ Perfusion System and during a challenging time of market and supply chain disruption during and post pandemic,” said Bill Kozy, Interim Chief Executive Officer and Board Chair. “We wish Marco the best in his retirement from LivaNova. We are confident in Franco and our experienced CP senior leadership team and expect a smooth transition.”

Poletti joined LivaNova, then Sorin Group, in 1991. He brings a depth of knowledge and experience in commercial strategy and execution in the CP market. Poletti has led global and regional divisions of the CP business and overseen various stages of product development and launches. Plus, he has held leadership roles in the Neuromodulation BU while at LivaNova.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230920458015/en/

LivaNova plc Stock

€58.00
0.870%
The LivaNova plc stock is trending slightly upwards today, with an increase of €0.50 (0.870%) compared to yesterday's price.
With 9 Buy predictions and not the single Sell prediction the community is currently very high on LivaNova plc.
As a result the target price of 66 € shows a slightly positive potential of 13.79% compared to the current price of 58.0 € for LivaNova plc.
Like: 0
Share
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments